TABLE 4.
Bladder recurrence‐free survival analysis of UTUC with DM patients.
| Variables | Crude Cox model | Adj Cox model | ||
|---|---|---|---|---|
| cHR (95% CI) | p | aHR (95% CI) | p | |
| Age | 1.029 (1.017–1.041) | < 0.001* | 1.027 (1.015–1.040) | < 0.001* |
| BMI | 0.974 (0.947–1.002) | 0.072 | ||
| CIS | ||||
| No | 1 | |||
| Yes | 1.202 (0.959–1.506) | 0.110 | ||
| Grade | ||||
| Low grade | 1 | |||
| High grade | 1.272 (0.945–1.711) | 0.112 | ||
| Location | ||||
| Renal pelvis | 1 | 1 | ||
| Ureter | 1.201 (0.959–1.503) | 0.110 | 1.238 (0.975–1.572) | 0.080 |
| Synchronous | 1.615 (1.246–2.092) | < 0.001* | 1.473 (1.117–1.942) | 0.006* |
| LVI | ||||
| No | 1 | |||
| Yes | 1.689 (1.329–2.145) | < 0.001* | ||
| Metastasis | ||||
| No | 1 | 1 | ||
| Yes | 2.009 (1.557–2.591) | < 0.001* | 1.645 (1.254–2.158) | < 0.001* |
| Metformin | ||||
| Without metformin | 1 | 1 | ||
| With metformin | 0.993 (0.79–1.248) | 0.953 | 1.034 (0.808–1.322) | 0.791 |
| Mutifocality | ||||
| No | 1 | |||
| Yes | 1.409 (1.154–1.72) | < 0.001* | ||
| Pathological N stage | ||||
| pN0/Nx | 1 | |||
| pN1/N2 | 2.152 (1.112–4.167) | 0.023* | ||
| eGFR (mL/min/1.73 m2) before surgery | 0.995 (0.991–0.999) | 0.009* | ||
| Pathological T stage | ||||
| pT < 2 | 1 | 1 | ||
| pT ≥ 2 | 1.724 (1.413–2.102) | < 0.001* | 1.429 (1.146–1.782) | 0.002* |
| Gender | ||||
| Male | 1 | 1 | ||
| Female | 0.645 (0.53–0.784) | < 0.001* | 0.639 (0.516–0.791) | < 0.001* |
| Laterality | ||||
| Left | 1 | |||
| Right | 1.005 (0.826–1.223) | 0.960 | ||
| Both | 1.125 (0.360–3.519) | 0.839 | ||
| Size | ||||
| < 1 cm | 1 | |||
| < 2 cm | 1.057 (0.643–1.738) | 0.826 | ||
| < 3 cm | 1.419 (0.868–2.318) | 0.163 | ||
| ≥ 3 cm | 1.500 (0.944–2.383) | 0.086 | ||
Abbreviations: BMI, body mass index; CI, confidence interval; CIS, carcinoma in situ; HR, hazard ratio; LVI, lymphovascular invasion.
*
p < 0.05.